Barrs Pharmaceuticals Secures R92m Hetero Investment

Original Article by Tamar Kahn | Business Day | 3 February 2026

Barrs Pharmaceuticals has exited business rescue after agreeing to sell a controlling stake to Hetero. The deal signals a reset for a local manufacturer that has faced both operational disruption and regulatory pressure. Business rescue consultant Karl Gribnitz announced that the Indian generics group’s South African subsidiary will acquire 78% of Barrs for R92m. The […]

Barrs Pharmaceuticals has exited business rescue after agreeing to sell a controlling stake to Hetero. The deal signals a reset for a local manufacturer that has faced both operational disruption and regulatory pressure. Business rescue consultant Karl Gribnitz announced that the Indian generics group’s South African subsidiary will acquire 78% of Barrs for R92m. The…

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here

More Posts

Mpox Cases in SA Rise as Local Transmission Accelerates

Mpox cases in South Africa are rising, mainly in the Western Cape. What the surge means for the healthcare industry.

Read more...

NHLS Scrambles as Pathology Services Funding Runs Dry

The NHLS is scrambling for new providers after funds for haematology pathology services ran dry, amid an R11.3bn provincial debt

Read more...

Momentum Group Posts Record Earnings

Momentum Group has posted record earnings, with normalised headline earnings up 13% to R7.06bn – beating its R7bn Impact target a year early.

Read more...